RE:EMA issueThe question which was asked was specifically about EMA, his answer was,
"the meeting is just round the corner it's coming up for NASH we are going to do it in a few week in a few months we will actually resubmit the protocol we are on schedule to dose first patient in Q3".
SPCEO1 wrote: Someone said Paul addressed the EMA issue in today's Bloom Burton call. I didn't hear that but may have missed it. In the Q&A, a EMA question was asked but due to the bad audio, I think Paul thought the question was about the FDA and answered it (actually re-answered it might be a better description since he had already addressed the FDA meeting) as if the question was again about the FDA meeting. So, I did not hear any new insight regarding the FDA on the call. Did I miss something?